| Browse All

Adial Pharmaceuticals, Inc. (ADIL)

Healthcare | Biotechnology | Glen Allen, United States | NasdaqCM
1.63 USD +0.00 (0.309%) ⇧ (April 17, 2026, 3:38 p.m. EDT)

Short-term: ★☆☆☆☆ | Long-term: ☆☆☆☆☆ | Dividends: ☆☆☆☆☆
Hot Take | April 11, 2026, 1:32 p.m. EDT

ADIL is currently experiencing significant volatility and uncertainty, with a recent price drop following a reverse stock split announcement. The stock's low price-to-book ratio and negative earnings suggest potential undervaluation, but the lack of consistent dividend payments and high financial risks make it unsuitable for long-term investment. Short-term traders may consider the recent dip as a buying opportunity, but the high beta and negative momentum indicators indicate a risky environment. Overall, ADIL is not a strong candidate for either short-term or long-term investment at this time.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
AutoARIMA ✓0.740990
AutoTheta0.803906
MSTL0.938431
AutoETS0.940083

Forecast horizon: 45 days | Selected: AutoARIMA

Forecast Reliability
Score 30%
H-stat 2.99
Ljung-Box p 0.000
Jarque-Bera p 0.000
Excess Kurtosis 1.62
Attribute Value
Sector Healthcare
Market Cap 2,320,451
Forward P/E -0.34
Beta 1.40
Website https://www.adial.com

Info Dump

Attribute Value
52 Week Change -0.9003077
Address1 4,870 Sadler Road
Address2 Suite 300
All Time High 5,900.0
All Time Low 1.54
Ask 1.64
Ask Size 1
Average Daily Volume10 Day 93,600
Average Daily Volume3 Month 96,967
Average Volume 96,967
Average Volume10Days 93,600
Beta 1.399
Bid 1.58
Bid Size 1
Book Value 4.749
City Glen Allen
Compensation As Of Epoch Date 1,767,139,200
Country United States
Crypto Tradeable 0
Currency USD
Current Price 1.625
Current Ratio 4.425
Custom Price Alert Confidence HIGH
Date Short Interest 1,774,915,200
Day High 1.655
Day Low 1.61
Display Name Adial Pharmaceuticals
Earnings Timestamp End 1,755,288,000
Earnings Timestamp Start 1,754,942,400
Ebitda -7,798,897
Ebitda Margins 0.0
Enterprise To Ebitda 0.457
Enterprise Value -3,567,905
Eps Current Year -6.59333
Eps Forward -4.795
Eps Trailing Twelve Months -11.93
Esg Populated 0
Exchange NCM
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 2.1454
Fifty Day Average Change -0.52040005
Fifty Day Average Change Percent -0.24256551
Fifty Two Week Change Percent -90.03077
Fifty Two Week High 30.25
Fifty Two Week High Change -28.625
Fifty Two Week High Change Percent -0.946281
Fifty Two Week Low 1.54
Fifty Two Week Low Change 0.08500004
Fifty Two Week Low Change Percent 0.055194832
Fifty Two Week Range 1.54 - 30.25
Financial Currency USD
First Trade Date Milliseconds 1,532,698,200,000
Float Shares 1,284,202
Forward Eps -4.795
Forward P E -0.33889467
Free Cashflow -3,768,275
Full Exchange Name NasdaqCM
Full Time Employees 5
Gmt Off Set Milliseconds -14,400,000
Gross Margins 0.0
Has Pre Post Market Data 1
Held Percent Insiders 0.07993
Held Percent Institutions 0.09906
Implied Shares Outstanding 1,427,970
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Last Split Date 1,770,336,000
Last Split Factor 1:25
Long Business Summary Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.
Long Name Adial Pharmaceuticals, Inc.
Market us_market
Market Cap 2,320,451
Market State REGULAR
Max Age 86,400
Message Board Id finmb_112638788
Most Recent Quarter 1,767,139,200
Net Income To Common -7,977,171
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 2,299,031
Number Of Analyst Opinions 3
Open 1.6308
Operating Cashflow -6,492,603
Operating Margins 0.0
Payout Ratio 0.0
Phone 804 487 8196
Previous Close 1.62
Price Eps Current Year -0.2464612
Price Hint 4
Price To Book 0.3421773
Profit Margins 0.0
Quick Ratio 4.21
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change 0.004999995
Regular Market Change Percent 0.30864167
Regular Market Day High 1.655
Regular Market Day Low 1.61
Regular Market Day Range 1.61 - 1.655
Regular Market Open 1.6308
Regular Market Previous Close 1.62
Regular Market Price 1.625
Regular Market Time 1,776,454,680
Regular Market Volume 68,437
Return On Assets -0.83205
Return On Equity -1.7073399
Sand P52 Week Change 0.36506534
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Shares Outstanding 1,427,970
Shares Percent Shares Out 0.0678
Shares Short 96,887
Shares Short Previous Month Date 1,772,150,400
Shares Short Prior Month 27,868
Short Name Adial Pharmaceuticals, Inc
Short Percent Of Float 0.0684
Short Ratio 0.62
Source Interval 15
State VA
Symbol ADIL
Target High Price 42.0
Target Low Price 8.0
Target Mean Price 23.33333
Target Median Price 20.0
Total Cash 5,881,217
Total Cash Per Share 4.119
Total Debt 0
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -11.93
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 6.8751
Two Hundred Day Average Change -5.2501
Two Hundred Day Average Change Percent -0.7636398
Type Disp Equity
Volume 68,437
Website https://www.adial.com
Zip 23,060